{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:39:46Z","timestamp":1790177986900,"version":"4.1.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T00:00:00Z","timestamp":1541980800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00393-018-0565-8","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T10:07:19Z","timestamp":1542017239000},"page":"952-957","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Ansprechen einer Dermatomyositis mit Lungenbeteiligung auf eine Januskinase-Inhibitor-Therapie","Response of dermatomyositis with lung involvement to Janus kinase inhibitor treatment"],"prefix":"10.1007","volume":"77","author":[{"given":"J.","family":"Hornig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Weinhage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. H.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Buerke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Pavenst\u00e4dt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gabri\u00ebls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,12]]},"reference":[{"issue":"5","key":"565_CR1","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1097\/WCO.0000000000000376","volume":"29","author":"O Benveniste","year":"2016","unstructured":"Benveniste O, Stenzel W, Allenbach Y (2016) Advances in serological diagnostics of inflammatory myopathies. Curr Opin Neurol 29(5):662\u2013673","journal-title":"Curr Opin Neurol"},{"issue":"11","key":"565_CR2","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2169\/internalmedicine.56.7956","volume":"56","author":"K Tokunaga","year":"2017","unstructured":"Tokunaga K, Hagino N (2017) Dermatomyositis with rapidly progressive interstitial lung disease treated with rituximab: a\u00a0report of 3 cases in Japan. Intern Med 56(11):1399\u20131403","journal-title":"Intern Med"},{"key":"565_CR3","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","volume":"152","author":"DJ Kurtzman","year":"2016","unstructured":"Kurtzman DJ, Wright NA, Lin J et\u00a0al (2016) Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment. JAMA Dermatol 152:944\u2013945","journal-title":"JAMA Dermatol"},{"key":"565_CR4","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2491","author":"JJ Paik","year":"2016","unstructured":"Paik JJ, Christopher-Stine L (2016) A case of refractory dermatomyositis responsive to tofacitinib. Semin Arthritis Rheum. \n                    https:\/\/doi.org\/10.2340\/00015555-2491","journal-title":"Semin Arthritis Rheum"},{"key":"565_CR5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.cyto.2014.11.026","volume":"73","author":"A Arshanapalli","year":"2015","unstructured":"Arshanapalli A, Shah M, Veerula V et\u00a0al (2015) The role of type I interferons and other cytokines in dermatomyositis. Cytokine 73:319\u2013325. \n                    https:\/\/doi.org\/10.1016\/j.cyto.2014.11.026","journal-title":"Cytokine"},{"key":"565_CR6","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/art.22382","volume":"56","author":"MR York","year":"2007","unstructured":"York MR et al (2007) A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum 56:1010\u20131020","journal-title":"Arthritis Rheum"},{"key":"565_CR7","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1136\/annrheumdis-2012-201586","volume":"72","author":"T Rose","year":"2013","unstructured":"Rose T, Grutzkau A, Hirseland H et al (2013) IFNalpha and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis 72:1639\u20131645","journal-title":"Ann Rheum Dis"},{"key":"565_CR8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1136\/ard.2011.150284","volume":"71","author":"S Rosengren","year":"2012","unstructured":"Rosengren S, Corr M, Firestein GS, Boyle DL (2012) The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann Rheum Dis 71:440\u2013447","journal-title":"Ann Rheum Dis"},{"key":"565_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pupt.2017.01.002","volume":"43","author":"E Calama","year":"2017","unstructured":"Calama E, Ramis I et\u00a0al (2017) Tofacitinib ameliorates inflammation in a\u00a0rat model of airway neutrophilia induced by inhaled LPS. Pulm Pharmacol Ther 43:60\u201367","journal-title":"Pulm Pharmacol Ther"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-018-0565-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0565-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0565-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:28:18Z","timestamp":1573518498000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-018-0565-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,12]]},"references-count":9,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["565"],"URL":"https:\/\/doi.org\/10.1007\/s00393-018-0565-8","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,12]]},"assertion":[{"value":"12 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Hornig und H.\u00a0Becker geben an, finanzielle Unterst\u00fctzung f\u00fcr Fortbildungsveranstaltungen von der Firma Pfizer und Lilly erhalten zu haben. U.\u00a0Schneider gibt an, Honorare f\u00fcr Vortr\u00e4ge und als Berater von der Firma Roche erhalten zu haben. T.\u00a0Weinhage, L.H.\u00a0Schmidt, B.\u00a0Buerke, H.\u00a0Pavenst\u00e4dt und G.\u00a0Gabri\u00ebls geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}